RetractedTrialThe Journal of international medical research2019

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.

Bin Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.